## Todd C Lee

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3481048/publications.pdf

Version: 2024-02-01

201674 133252 4,273 132 27 59 citations h-index g-index papers 142 142 142 8002 docs citations times ranked citing authors all docs

#	Article	IF	Citations
1	A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19. New England Journal of Medicine, 2020, 383, 517-525.	27.0	1,081
2	Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19. Annals of Internal Medicine, 2020, 173, 623-631.	3.9	444
3	Comparison of Saliva and Nasopharyngeal Swab Nucleic Acid Amplification Testing for Detection of SARS-CoV-2. JAMA Internal Medicine, 2021, 181, 353.	5.1	269
4	Continuous Proton Pump Inhibitor Therapy and the Associated Risk of Recurrent <i>Clostridium difficile</i> Infection. JAMA Internal Medicine, 2015, 175, 784.	5.1	184
5	Review: Hydroxychloroquine and Chloroquine for Treatment of SARS-CoV-2 (COVID-19). Open Forum Infectious Diseases, 2020, 7, ofaa130.	0.9	160
6	Hydroxychloroquine as Pre-exposure Prophylaxis for Coronavirus Disease 2019 (COVID-19) in Healthcare Workers: A Randomized Trial. Clinical Infectious Diseases, 2021, 72, e835-e843.	5.8	103
7	Remdesivir for the treatment of patients in hospital with COVID-19 in Canada: a randomized controlled trial. Cmaj, 2022, 194, E242-E251.	2.0	103
8	Staphylococcus aureus bacteraemia mortality: a systematic review and meta-analysis. Clinical Microbiology and Infection, 2022, 28, 1076-1084.	6.0	73
9	Diagnostic accuracy of serum $(1-3)$ - $\hat{l}^2$ -D-glucan for Pneumocystis jirovecii pneumonia: a systematic review and meta-analysis. Clinical Microbiology and Infection, 2020, 26, 1137-1143.	6.0	72
10	Inhaled and intranasal ciclesonide for the treatment of covid-19 in adult outpatients: CONTAIN phase II randomised controlled trial. BMJ, The, 2021, 375, e068060.	6.0	52
11	Remdesivir for the treatment of COVID-19: a systematic review and meta-analysis. Clinical Microbiology and Infection, 2022, 28, 1203-1210.	6.0	50
12	The MedSafer Study: A Controlled Trial of an Electronic Decision Support Tool for Deprescribing in Acute Care. Journal of the American Geriatrics Society, 2019, 67, 1843-1850.	2.6	49
13	Characteristics and outcomes of patients with COVID-19 admitted to hospital and intensive care in the first phase of the pandemic in Canada: a national cohort study. CMAJ Open, 2021, 9, E181-E188.	2.4	49
14	Fluvoxamine for Outpatient Management of COVID-19 to Prevent Hospitalization. JAMA Network Open, 2022, 5, e226269.	5.9	48
15	The MedSafer Study—Electronic Decision Support for Deprescribing in Hospitalized Older Adults. JAMA Internal Medicine, 2022, 182, 265.	5.1	44
16	Beliefs and practices of Ontario midwives about influenza immunization. Vaccine, 2005, 23, 1574-1578.	3.8	38
17	Safety of Hydroxychloroquine Among Outpatient Clinical Trial Participants for COVID-19. Open Forum Infectious Diseases, 2020, 7, ofaa500.	0.9	38
18	Both New and Chronic Potentially Inappropriate Medications Continued at Hospital Discharge Are Associated With Increased Risk of Adverse Events. Journal of the American Geriatrics Society, 2020, 68, 1184-1192.	2.6	38

#	Article	IF	CITATIONS
19	Is convalescent plasma futile in COVID-19? A Bayesian re-analysis of the RECOVERY randomized controlled trial. International Journal of Infectious Diseases, 2021, 109, 114-117.	3.3	38
20	Colistin Nephrotoxicity: Meta-Analysis of Randomized Controlled Trials. Open Forum Infectious Diseases, 2021, 8, ofab026.	0.9	38
21	Time-Series Analysis of Health Care–Associated Infections in a New Hospital With All Private Rooms. JAMA Internal Medicine, 2019, 179, 1501.	5.1	37
22	Back to the Future: Penicillin-Susceptible Staphylococcus aureus. American Journal of Medicine, 2016, 129, 1331-1333.	1.5	36
23	Effect of an Electronic Medication Reconciliation Intervention on Adverse Drug Events. JAMA Network Open, 2019, 2, e1910756.	5.9	36
24	Generating randomized trial evidence to optimize treatment in the COVID-19 pandemic. Cmaj, 2020, 192, E405-E407.	2.0	36
25	Reduction of inappropriate exit prescriptions for proton pump inhibitors: A beforeâ€after study using education paired with a webâ€based qualityâ€improvement tool. Journal of Hospital Medicine, 2015, 10, 281-286.	1.4	34
26	Adjunctive Daptomycin in the Treatment of Methicillin-susceptible <i>Staphylococcus aureus</i> Bacteremia: A Randomized, Controlled Trial. Clinical Infectious Diseases, 2021, 72, e196-e203.	5.8	34
27	Rates of Overtreatment and Treatment-Related Adverse Effects Among Patients With Subsegmental Pulmonary Embolism. JAMA Internal Medicine, 2018, 178, 1272.	5.1	30
28	Potential harms of proton pump inhibitor therapy: rare adverse effects of commonly used drugs. Cmaj, 2016, 188, 657-662.	2.0	29
29	Improving patient safety and efficiency of medication reconciliation through the development and adoption of a computer-assisted tool with automated electronic integration of population-based community drug data: the RightRx project. Journal of the American Medical Informatics Association: IAMIA, 2018, 25, 482-495.	4.4	29
30	Proton pump inhibitor use and risk for recurrent Clostridioides difficile infection: a systematic review and meta-analysis. Clinical Microbiology and Infection, 2021, 27, 697-703.	6.0	29
31	<scp>COVIDâ€6AFER</scp> : Deprescribing Guidance for Hydroxychloroquine Drug Interactions in Older Adults. Journal of the American Geriatrics Society, 2020, 68, 1636-1646.	2.6	29
32	EMPOWERing Hospitalized Older Adults to Deprescribe Sedative Hypnotics: A Pilot Study. Journal of the American Geriatrics Society, 2018, 66, 1186-1189.	2.6	27
33	MRSA colonization status as a predictor of clinical infection: A systematic review and meta-analysis. Journal of Infection, 2018, 77, 489-495.	3.3	27
34	Longitudinal Plasma Proteomics Analysis Reveals Novel Candidate Biomarkers in Acute COVID-19. Journal of Proteome Research, 2022, 21, 975-992.	3.7	27
35	Acute Cardiac Injury in Coronavirus Disease 2019 and Other Viral Infections—A Systematic Review and Meta-Analysis. Critical Care Medicine, 2021, 49, 1558-1566.	0.9	26
36	IL-6 blockade for COVID-19: a global scientific call to arms. Lancet Respiratory Medicine, the, 2021, 9, 438-440.	10.7	25

#	Article	IF	CITATIONS
37	Web and phone-based COVID-19 syndromic surveillance in Canada: A cross-sectional study. PLoS ONE, 2020, 15, e0239886.	2.5	24
38	Use of Novel Strategies to Develop Guidelines for Management of Pyogenic Osteomyelitis in Adults. JAMA Network Open, 2022, 5, e2211321.	5.9	24
39	Diastolic Hypotension May Attenuate Benefits from Intensive Systolic Targets: Secondary Analysis of a Randomized Controlled Trial. American Journal of Medicine, 2018, 131, 1228-1233.e1.	1.5	22
40	Non-invasive diagnosis of Pneumocystis jirovecii pneumonia: a systematic review and meta-analysis. Clinical Microbiology and Infection, 2022, 28, 23-30.	6.0	22
41	Mindfulness-Based Laboratory Reduction: Reducing Utilization Through Trainee-Led Daily †Time Outs'. American Journal of Medicine, 2017, 130, e241-e244.	1.5	21
42	A Rose by Any Other Name: Ketoacidosis Due to SGLT2 Inhibitors Reveals Latent Autoimmune Diabetes. American Journal of Medicine, 2018, 131, e1-e3.	1.5	21
43	Remdesivir and systemic corticosteroids for the treatment of COVID-19: A Bayesian re-analysis. International Journal of Infectious Diseases, 2021, 104, 671-676.	3.3	21
44	Association of Lower Diagnostic Yield With High Users of CT Pulmonary Angiogram. JAMA Internal Medicine, 2018, 178, 412.	5.1	20
45	Pattern of Inpatient Laxative Use. JAMA Internal Medicine, 2016, 176, 1216.	5.1	19
46	Post-exposure prophylaxis or pre-emptive therapy for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): study protocol for a pragmatic randomized-controlled trial. Canadian Journal of Anaesthesia, 2020, 67, 1201-1211.	1.6	19
47	Low-Dose TMP-SMX in the Treatment of Pneumocystis jirovecii Pneumonia: A Systematic Review and Meta-analysis. Open Forum Infectious Diseases, 2020, 7, ofaa112.	0.9	19
48	Off-label Use of Quetiapine in Medical Inpatients and Postdischarge. JAMA Internal Medicine, 2016, 176, 1390.	5.1	18
49	An observational cohort study of hydroxychloroquine and azithromycin for COVID-19: (Can't Get No) Satisfaction. International Journal of Infectious Diseases, 2020, 98, 216-217.	3.3	18
50	Outpatient Therapies for COVID-19: How Do We Choose?. Open Forum Infectious Diseases, 2022, 9, ofac008.	0.9	18
51	A tumour lysis syndrome in a chemotherapy naive patient with metastatic pancreatic adenocarcinoma. BMJ Case Reports, 2015, 2015, bcr2014207748-bcr2014207748.	0.5	16
52	Accuracy and generalizability of using automated methods for identifying adverse events from electronic health record data: a validation study protocol. BMC Health Services Research, 2017, 17, 147.	2,2	15
53	Failure to follow medication changes made at hospital discharge is associated with adverse events in 30 days. Health Services Research, 2020, 55, 512-523.	2.0	15
54	Angiotensin Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors in COVID-19: Meta-analysis/Meta-regression Adjusted for Confounding Factors. CJC Open, 2021, 3, 965-975.	1.5	15

#	Article	IF	Citations
55	Nirmatrelvir-ritonavir for COVID-19. Cmaj, 2022, 194, E218-E218.	2.0	15
56	Using MRSA Screening Tests To Predict Methicillin Resistance in Staphylococcus aureus Bacteremia. Antimicrobial Agents and Chemotherapy, 2016, 60, 7444-7448.	3.2	14
57	Adverse Drug Events in Older Adults: Review of Adjudication Methods in Deprescribing Studies. Journal of the American Geriatrics Society, 2020, 68, 1594-1602.	2.6	14
58	Deprescribing Proton Pump Inhibitors. JAMA Internal Medicine, 2020, 180, 571.	5.1	14
59	Hydroxychloroquine for COVID19: The curtains close on a comedy of errors. The Lancet Regional Health Americas, 2022, 11, 100268.	2.6	14
60	Beta-Lactam/Beta-Lactamase Inhibitor Therapy for Potential AmpC-Producing Organisms: A Systematic Review and Meta-Analysis. Open Forum Infectious Diseases, 2019, 6, .	0.9	13
61	Drug Interactions With Nirmatrelvir-Ritonavir in Older Adults Using Multiple Medications. JAMA Network Open, 2022, 5, e2220184.	5.9	13
62	Inpatient Attire. JAMA Internal Medicine, 2014, 174, 1865.	5.1	11
63	Challenges at Care Transitions: Failure to Follow Medication Changes Made at Hospital Discharge. American Journal of Medicine, 2019, 132, 1216-1224.e5.	1.5	11
64	Comparative effectiveness of amphotericin B, azoles and echinocandins in the treatment of candidemia and invasive candidiasis: A systematic review and network metaâ€analysis. Mycoses, 2021, 64, 1098-1110.	4.0	11
65	Inhaled corticosteroids for outpatients with COVID-19: a meta-analysis. European Respiratory Journal, 2022, 59, 2102921.	6.7	11
66	Expert Recommendations on Frequency of Utilization of Common Laboratory Tests in Medical Inpatients: a Canadian Consensus Study. Journal of General Internal Medicine, 2019, 34, 2786-2795.	2.6	10
67	The infectious thyroid nodule: a case report of mucormycosis associated with ibrutinib therapy. Journal of Otolaryngology - Head and Neck Surgery, 2019, 48, 49.	1.9	10
68	Radiographic features in investigated for Pneumocystis jirovecii pneumonia: a nested case-control study. BMC Infectious Diseases, 2020, 20, 492.	2.9	10
69	Piperacillin–tazobactam versus meropenem for treatment of bloodstream infections caused by third-generation cephalosporin-resistant Enterobacteriaceae: a study protocol for a non-inferiority open-label randomised controlled trial (PeterPen). BMJ Open, 2021, 11, e040210.	1.9	10
70	Ongoing Citations of a Retracted Study Involving Cardiovascular Disease, Drug Therapy, and Mortality in COVID-19. JAMA Internal Medicine, 2021, 181, 1535.	5.1	10
71	Staphylococcus aureus bacteremia mortality across country income groups: A secondary analysis of a systematic review. International Journal of Infectious Diseases, 2022, 122, 405-411.	3.3	10
72	Increasing Rates of Penicillin Sensitivity in Staphylococcus aureus. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	9

#	Article	IF	CITATIONS
73	Association of Medical Microbiology and Infectious Disease Canada treatment practice guidelines for <i>Clostridium difficile</i> infection. Jammi, 2018, 3, 71-92.	0.5	9
74	An online educational module on transfusion safety and appropriateness for resident physicians: a controlled before–after quality-improvement study. CMAJ Open, 2019, 7, E492-E496.	2.4	9
75	On the Treatment of <i>Pneumocystis jirovecii</i> Pneumonia: Current Practice Based on Outdated Evidence. Open Forum Infectious Diseases, 2021, 8, ofab545.	0.9	9
76	Lessons Learned From Conducting Internet-Based Randomized Clinical Trials During a Global Pandemic. Open Forum Infectious Diseases, 2021, 8, ofaa602.	0.9	9
77	What Is the Optimal Follow-up Length for Mortality in <i>Staphylococcus aureus</i> Bacteremia? Observations From a Systematic Review of Attributable Mortality. Open Forum Infectious Diseases, 2022, 9, ofac096.	0.9	9
78	Novel low-resource intervention reduces urinary catheter use and associated urinary tract infections: Role of outcome measure bias?. American Journal of Infection Control, 2015, 43, 348-353.	2.3	8
79	Screening swabs surpass traditional risk factors as predictors of MRSA bacteremia. BMC Infectious Diseases, 2018, 18, 270.	2.9	8
80	Proton Pump Inhibitors Versus Histamine-2 Receptor Antagonists Likely Increase Mortality in Critical Care: An Updated Meta-Analysis. American Journal of Medicine, 2021, 134, e184-e188.	1.5	8
81	Evaluation of the cost-effectiveness of evolocumab in the FOURIER study: a Canadian analysis. CMAJ Open, 2018, 6, E162-E167.	2.4	7
82	Daptomycin versus placebo as an adjunct to beta-lactam therapy in the treatment of Staphylococcus aureus bacteremia: study protocol for a randomized controlled trial. Trials, 2018, 19, 297.	1.6	7
83	Potentially Inappropriate Medication Use in Older Adults in the Preoperative Period: A Retrospective Study of a Noncardiac Surgery Cohort. Drugs - Real World Outcomes, 2020, 7, 171-178.	1.6	7
84	Retrospective Cohort Study of the Prevalence of Off-label Gabapentinoid Prescriptions in Hospitalized Medical Patients. Journal of Hospital Medicine, 2019, 14, 547-550.	1.4	7
85	How generalizable are randomized controlled trials (RCTs) in <i>Staphylococcus aureus</i> bacteremia? A description of the mortality gap between RCTs and observational studies. Clinical Infectious Diseases, 2022, , .	5 <b>.</b> 8	7
86	Rebound adrenal insufficiency after withdrawal of ritonavir in a 65-year-old man using inhaled budesonide. Cmaj, 2017, 189, E1188-E1191.	2.0	6
87	Group B Streptococcus tricuspid valve endocarditis with subsequent septic embolization to the pulmonary artery: A case report following elective abortion. Obstetric Medicine, 2018, 11, 39-44.	1.1	5
88	Predictive factors of Clostridioides difficile infection in hospitalized patients with new diarrhea: A retrospective cohort study. PLoS ONE, 2018, 13, e0207128.	2.5	5
89	Real-world Time to Positivity of 2 Widely Used Commercial Blood Culture Systems in Patients With Severe Manifestations of Sepsis: An Analysis of the FABLED Study. Open Forum Infectious Diseases, 2020, 7, ofaa371.	0.9	5
90	Hand hygiene "hall monitors― Leveraging the Hawthorne effect. American Journal of Infection Control, 2018, 46, 706-707.	2.3	4

#	Article	IF	Citations
91	Stability of Biological Activity of Frozen $\hat{l}^2$ -lactams over Time as Assessed by Time-Lapsed Broth Microdilutions. Antibiotics, 2019, 8, 165.	3.7	4
92	In vitro synergy of $\hat{l}^2$ -lactam combinations against KPC-producing Klebsiella pneumoniae strains. Journal of Antimicrobial Chemotherapy, 2019, 74, 3515-3520.	3.0	4
93	Clinician Understanding of Cholesterol Treatment Guidelines. JAMA - Journal of the American Medical Association, 2015, 313, 2381.	7.4	3
94	Treatment for <i>Clostridium difficile</i> Infection in Adults. JAMA - Journal of the American Medical Association, 2015, 313, 1974.	7.4	3
95	Insomnia in the Hospital—Not Just a Bad Dream. JAMA Internal Medicine, 2016, 176, 1253.	5.1	3
96	Hepatitis B testing practices at a tertiary care centre and their associated costs: A retrospective analysis. PLoS ONE, 2019, 14, e0219347.	2.5	3
97	Triazole Antifungal Susceptibility Patterns among <i>Aspergillus</i> Species in Québec, Canada. Journal of Clinical Microbiology, 2019, 57, .	3.9	3
98	Using VRE screening tests to predict vancomycin resistance in enterococcal bacteremia. Infection Control and Hospital Epidemiology, 2020, 41, 425-429.	1.8	3
99	Evaluation of a Mobile Application to Enhance Medication Management Following Hospital Discharge: Study Protocol for a Pilot Randomized Controlled Trial. Studies in Health Technology and Informatics, 2019, 264, 1929-1930.	0.3	3
100	Organ dysfunction and death in patients admitted to hospital with COVID-19 in pandemic waves 1 to 3 in British Columbia, Ontario and Quebec, Canada: a cohort study. CMAJ Open, 2022, 10, E379-E389.	2.4	3
101	Ezetimibe Use Remains Common Among MedicalÂlnpatients. American Journal of Medicine, 2015, 128, 193-195.	1.5	2
102	Reduction of Central Venous Catheter Use in Medical Inpatients Through Regular Physician Audits Using an Online Tool. JAMA Internal Medicine, 2015, 175, 1232.	5.1	2
103	A point prevalence study of urinary catheter use among teaching hospitals with and without reduction programs. Journal of Hospital Medicine, 2016, 11, 799-800.	1.4	2
104	River otter bite in a 52-year-old woman: managing animal bites. Cmaj, 2016, 188, E513-E516.	2.0	2
105	Missed Opportunities for Deprescription. JAMA Internal Medicine, 2017, 177, 1028.	5.1	2
106	Factors Associated With 30-Day Mortality Rate in Respiratory Infections Caused by Streptococcus pneumoniae. Clinical Infectious Diseases, 2018, 66, 1282-1285.	5.8	2
107	Clinical Trials Increase Off-Study Drug Use: A Segmented Time-Series Analysis. Open Forum Infectious Diseases, 2020, 7, ofaa449.	0.9	2
108	Staphylococcus aureus bacteraemia: does duration matter?. Lancet Infectious Diseases, The, 2020, 20, 1353-1354.	9.1	2

#	Article	IF	CITATIONS
109	Tocilizumab versus the Covid19 tempest: All's well that ends well or much ado about nothing?. Clinical Microbiology and Infection, 2021, 27, 158-159.	6.0	2
110	Inpatient Z-drug use commonly exceeds safe dosing recommendations. PLoS ONE, 2017, 12, e0177645.	2.5	2
111	Ebola. Cmaj, 2014, 186, E589-E589.	2.0	1
112	Using MRSA Screening Tests to Predict Methicillin Resistance in Staphylococcus aureus Bacteremia. Open Forum Infectious Diseases, 2016, 3, .	0.9	1
113	"Explainable―Weight Loss. JAMA Internal Medicine, 2017, 177, 420.	5.1	1
114	Chest Pain and Supplemental Oxygen. JAMA Internal Medicine, 2017, 177, 266.	5.1	1
115	The Reply. American Journal of Medicine, 2018, 131, e157.	1.5	1
116	The Reply. American Journal of Medicine, 2019, 132, e24-e25.	1.5	1
117	Re: †The renal safety of a single dose of gentamicin in patients with sepsis in the emergency department' by Cobussen et al Clinical Microbiology and Infection, 2021, 27, 299-300.	6.0	1
118	Probable Immortal Time Bias in Comparison of Daptomycin and Vancomycin for Methicillin-resistant <i>Staphylococcus Aureus </i> Bloodstream Infections. Clinical Infectious Diseases, 2021, 73, 1127-1128.	5.8	1
119	Assessment of Piperacillin-Tazobactam-Meropenem Synergy against Serine Carbapenemase-Producing Enterobacterales Using Time-Kill Assays. Antimicrobial Agents and Chemotherapy, 2021, 65, .	3.2	1
120	Handheld infrared thermometer to evaluate cellulitis: the HI-TEC study. Clinical Microbiology and Infection, 2021, 27, 1814-1819.	6.0	1
121	Tenofovir-induced osteomalacia with hypophosphataemia. BMJ Case Reports, 2021, 14, e240387.	0.5	1
122	MedSafer to Support Deprescribing for Residents of Long-Term Care: a Mixed-Methods Study. Canadian Geriatrics Journal, 2022, 25, 175-182.	1.2	1
123	Costs of Inpatient Medications: Do Dispensing and Nursing Fees Lead to Overestimates?â€"Reply. JAMA Internal Medicine, 2016, 176, 1882.	5.1	0
124	The empress of subterfuge: cancer of the fallopian tube presenting with malapropism. Lancet, The, 2017, 390, 1003-1004.	13.7	0
125	Reply to Volpicelli et al. Clinical Infectious Diseases, 2021, 73, 168-169.	5.8	0
126	The Reply. American Journal of Medicine, 2021, 134, e536-e537.	1.5	0

## TODD C LEE

#	Article	IF	CITATIONS
127	Spread and scale of an electronic deprescribing software to improve health outcomes of older adults living in nursing homes: study protocol for a stepped wedge cluster randomized trial. Trials, 2021, 22, 763.	1.6	0
128	Web and phone-based COVID-19 syndromic surveillance in Canada: A cross-sectional study. , 2020, 15, e0239886.		0
129	Web and phone-based COVID-19 syndromic surveillance in Canada: A cross-sectional study. , 2020, 15, e0239886.		O
130	Web and phone-based COVID-19 syndromic surveillance in Canada: A cross-sectional study. , 2020, 15, e0239886.		0
131	Web and phone-based COVID-19 syndromic surveillance in Canada: A cross-sectional study. , 2020, 15, e0239886.		0
132	Allocated but not treated: the silent 16%. Lancet, The, 2022, 399, 1775.	13.7	0